Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus

NCT ID: NCT02991547

Last Updated: 2024-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

3 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2018-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out more information about patients who have cancer (adenocarcinoma) of the esophagus or gastroesophageal junction (GEJ) who have been treated with chemotherapy and radiation but have not had surgery. The study will follow patients for 5 years to monitor for their cancer and to see how the standard medical care affects the daily life of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenocarcinoma Esophagus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adenocarcinoma of esophagus or gastroesophageal junction (nidus of the cancer within 5 cm from the gastroesophageal junction) confirmed by biopsy with clinical stage I, II, or III. The superficial adenocarcinoma of the esophagus will be excluded.
* Received no previous treatment for esophageal cancer.
* Measurable or evaluable disease
* ECOG performance status: 0 to 2 that is able to perform activities of daily living with minimal assistance
* Adequate bone marrow function (hemoglobulin ≥8 g/dl, neutrophil ≥1.5x109/L and platelet ( ≥100x109/L)
* Adequate liver function

* Bilirubin normal, Meets 1 of the following criteria:
* Alkaline phosphatase (AP) normal AND AST/ALT ≤ 5 times upper limit of normal (ULN)
* AP ≤ 2.5 times ULN AND AST/ALT ≤ 1.5 times ULN
* AP ≤ 5 times ULN AND AST/ALT normal
* Adequate kidney function (creatinine ≤1.5 UNL and creatinine clearance ≥ 60 )
* Be at least 4 weeks from recent major surgical procedures.
* Patients must be able to understand the nature of the study and give written informed consent
* At least one measurable lesion on CT, MRI or esophageal barium exam.

Exclusion Criteria

* Age \< 18 years and \>80 years
* Contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or hematemesis
* Participating in other clinical trials
* Pregnancy
* Clinically significant and uncontrolled major medical conditions including but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements
* any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Guthrie Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joyson Poulose, MD

Role: STUDY_DIRECTOR

Guthrie Medical Group, PC/Robert Packer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guthrie Corning Hospital

Corning, New York, United States

Site Status

Guthrie Medical Group, PC/Robert Packer Hospital

Sayre, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1611-55

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.